Cytokinetics, The Mended Hearts, Inc., and WomenHeart Launch Initiative for Clinical Trial Engagement

In a significant move to advance cardiovascular health, Cytokinetics, Incorporated CYTK, a pioneering biopharmaceutical company, has joined forces with two leading patient advocacy groups, The Mended Hearts, Inc., and WomenHeart: The National Coalition for Women with Heart Disease. Together, they announced the initiation of ENACT, a groundbreaking program designed to foster increased patient involvement in cardiovascular clinical trials. This announcement, made on February 28, 2024, details the collaborative efforts to address challenges faced by patients and to enhance their role in clinical research.

Empowering Patients through ENACT

The ENACT initiative, which stands for Empower, Navigate, Advocate, Connect, and Transform, represents a comprehensive strategy to engage and empower patients in the cardiovascular community. It aims to provide tools and support for patients to navigate the clinical trial landscape, advocate for their own health, connect with research opportunities, and transform patient involvement in clinical treatment development. This initiative is particularly significant as it may lead to more inclusive research and potentially improved therapeutic options for those suffering from heart disease.

About Cytokinetics

Cytokinetics, Incorporated, headquartered in South San Francisco, is at the forefront of developing innovative muscle activators and inhibitors. As an advanced stage biopharmaceutical company, Cytokinetics is focused on developing potential treatments for debilitating diseases through their deep-rooted commitment to muscle biology and related mechanisms. The collaboration with The Mended Hearts, Inc. and WomenHeart underscores the company's dedication to addressing unmet patient needs and improving health outcomes.

Cytokinetics, ClinicalTrials, Cardiovascular